Clinical Trials Browser

OTHER × Gemcitabine × Lymphoid × Clear all

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01679119 2026-04-07

INCA

Phase 2 Completed

129 enrolled 7 charts

Lymphoma, Large B-Cell, Diffuse

NCT07451652 2026-04-01

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04960618 2026-03-23

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Phase 2 Active not recruiting

Mycosis Fungoides, Sezary Syndrome

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Not yet recruiting

Hodgkin Disease

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

Hodgkin Disease

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

Hodgkin Disease, Recurrence

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02750670 2025-06-22

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT01701986 2025-02-28

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

64 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Phase 3 Recruiting

Hodgkin Disease

NCT03366272 2025-01-28

NIVEAU

Phase 2/3 Completed

Lymphoma, Non-Hodgkin

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Phase 2 Completed

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT02295722 2024-07-08

GEMHDM2014

Phase 1/2 Terminated

Lymphoma, Follicular

NCT05105412 2024-07-08

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral

NCT03434262 2024-05-31

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Phase 1 Completed

Choroid Plexus Carcinoma, Microphthalmia, Isolated, with Coloboma 5, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Lymphoma, Follicular, Medulloblastoma, Meningioma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pinealoma, Recurrence, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT00863369 2024-03-20

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

33 enrolled 14 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06211881 2024-01-18

Chi-GVM Regimen for the Treatment of R/R PTCL

Phase NA Unknown

Lymphoma, T-Cell, Peripheral

NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00574496 2023-09-28

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Phase 2 Completed

25 enrolled 10 charts

Hodgkin Disease, Lymphoma, Recurrence

NCT04022005 2023-09-11

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT04156828 2023-06-29

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Phase NA Unknown

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2 Terminated

5 enrolled 7 charts

Lymphoma, T-Cell

NCT03422523 2022-08-22

ARGO

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02414724 2022-07-25

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Terminated

Lymphoma

NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Phase 3 Unknown

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT02741388 2021-12-07

SELINDA

Phase 1 Completed

Lymphoma, Lymphoma, B-Cell

NCT01535924 2021-11-19

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 1/2 Completed

26 enrolled 13 charts

Hodgkin Disease, Recurrence

NCT02733458 2021-09-14

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

Phase NA Completed

Lymphoma, Extranodal NK-T-Cell

NCT04999878 2021-08-11

RUE-DDGP

Phase 4 Unknown

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03259529 2021-06-07

BeGeRN

Phase 1/2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

Lymphoma, Extranodal NK-T-Cell